All news

Avalyn falls below 50-day average as Morgan Stanley cuts target

Alpha Vantage · MarketBeat · · AI-summarised by FinFlash

Avalyn Pharma (NASDAQ:AVLN) shares dropped below their 50-day moving average to $27.92 after Morgan Stanley lowered its price target from $57 to $53, while maintaining an "Overweight" rating. Despite the downgrade, the stock holds a "Moderate Buy" consensus and a $59.20 average price target from analysts. The company also reported a quarterly loss of $0.67 per share, missing consensus estimates.

Read original source

AVLN company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.